Race for a Vaccine

Vaccine Progress Brings Hope

A U.S. drug company recently said that it’s in late-stage trials for its coronavirus vaccine and reported that it could be given to Americans as early as the end of the year.¹

Great news. But it seems like every few days there’s a new update on a clinical trial for COVID-19. So we took the opportunity to check out the overall status for the development of a vaccine.

Much to our surprise, we learned that more than 150 vaccines are in development across the world. Hopes are high that at least one of these vaccines can be brought to market in record time to help manage the global crisis.²

In the past, it has taken 10 to 15 years to develop a vaccine that’s ready for the market. The vaccine for the mumps, for example, took four years in the 1960s.²

Safety Remains a Priority

Along with the rapid development, there has been some fear that the process may be moving along too quickly without the proper checks and balances. On September 8, nine drug companies attempted to ease those concerns, releasing a letter saying they would prioritize safety and uphold “the integrity of the scientific process” in their efforts to develop coronavirus vaccines.³

Potential Market Impact

News about potential vaccines may continue to influence financial markets. Vaccine progress could also affect industries such as travel and leisure. At least one airline company believes a vaccine may be critical to the aviation industry’s recovery.⁴

For guidance on navigating market changes during uncertain times, what is volatility in stocks and market trends are key concepts to understand.

Staying Informed

Like you, we are closely watching developments and hoping for news that could help end the coronavirus crisis. If you have concerns about COVID-19 or its financial impact, please contact us. We welcome the chance to speak with you.

^{2. NationalGreographic.com, September 9, 2020}

^{3. USNews.com, September 8, 2020}

^{4. CNBC.com, September 13, 2020}

Important Information

Any companies referenced are for illustrative purposes only. Keep in mind that investing involves risks; therefore, you should make investment decisions based on your own goals, time horizon, and tolerance for risk. Additionally, the return and principal value of investments will fluctuate as market conditions change. When sold, investments may be worth more or less than their original cost.

The content in this material comes from sources believed to be accurate. However, the information is not intended as tax or legal advice. Please consult legal or tax professionals for guidance specific to your situation.

FMG Suite, LLC developed and produced this material to provide information on topics of interest. Importantly, FMG Suite is not affiliated with the named representative, broker-dealer, or any state- or SEC-registered investment advisory firm. Therefore, the opinions expressed in this material are for general information only and should not be considered a solicitation to buy or sell any security.

FAQ:

1. How many COVID-19 vaccines are currently in development?

Over 150 vaccines are in development worldwide, with several in late-stage clinical trials aiming for regulatory approval by the end of the year.

2. When could a COVID-19 vaccine be available in the U.S.?

Some pharmaceutical companies estimate a vaccine could be available as early as the end of 2020, though availability depends on trial results, regulatory review, and safety approvals.

3. How long does it normally take to develop a vaccine?

Typically, vaccines take 10–15 years to develop. For example, the mumps vaccine in the 1960s took four years. COVID-19 vaccines are being fast-tracked due to global urgency.

4. Are COVID-19 vaccines being developed safely?

Yes. Nine major drug companies pledged to prioritize safety and scientific integrity. Clinical trials follow strict protocols to ensure vaccines are safe before public use.

5. How could a COVID-19 vaccine affect the stock market?

Positive vaccine news often boosts market optimism, especially for sectors hit hardest by the pandemic, such as travel, leisure, and airlines. Investors may react to progress updates in vaccine trials.

6. Which industries could benefit most from a COVID-19 vaccine?

Industries likely to benefit include:

• Travel and airlines

• Hospitality and tourism

• Entertainment and leisure

• Retail and consumer services

7. How do vaccine trials work?

Vaccine trials occur in three phases:

1. Phase 1: Tests safety and dosage on a small group

2. Phase 2: Expands testing to hundreds of participants to monitor efficacy

3. Phase 3: Large-scale trials with thousands to confirm safety and effectiveness

8. Can COVID-19 vaccines guarantee an immediate end to the pandemic?

While vaccines are a critical tool, herd immunity, public compliance, and continued safety measures are also essential. Full recovery will take time even after a vaccine becomes available.

9. How can individuals stay informed about COVID-19 vaccine progress?

Reliable sources include:

• CDC and FDA websites

• Trusted media outlets like CNBC, WSJ, and Reuters

• Updates from pharmaceutical companies conducting trials

10. How should investors approach vaccine-related market news?

Investors should focus on long-term goals, avoid reacting impulsively to daily headlines, and consult financial professionals to adjust portfolios wisely in response to vaccine developments.